The FDA has improved CUITY, a new drug developed to improve nearsightedness.
Michael Seveoino, MD., who is vice chairman and president of Abvie, said, “We are proud to offer CUITY as a first-of-its kind once-daily eye drop that we believe will change the way people and their eye doctors approach presbyopia.”
Presbyopia is an eye condition that develops after age 40 in many, causing blurry vision or difficulty for a person to see close-up objects clearly. Additionally, it is a progressive condition as well.
Known as near vision, presbyopia has been treated by the use of prescription glasses, and those who suffer from the condition have difficulty reading without glasses.
Three clinical studies involving 750 participants were conducted with one of each of the groups receiving a placebo and the other participants in the three groups being treated with CUITY.
Each participant received one drop per day, the placebo groups with a harmless substance and the other groups with CUITY. Those groups that received CUITY improved their reading three lines better on the eye chart while the placebo groups made no improvement.
As for side effects, the CUITY groups reported only two side effects, redness of eyes and headaches, and that was only five percent of those who participated.
CUITY is pilacarpine HCI ophthalmic solution, and the one per day eye drop treatment does not impair distance vision while working to improve near vision as early as 15 minutes, an improvement that lasts six hours.